Good afternoon, everyone, and thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the fourth quarter and full year of 2022. Before turning the call over to management, I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 as amended. As set forth in our press release, forward-looking statements involve risks and uncertainties that may affect the company's business and prospects, including those discussed in our filings with the SEC, which include, among other things, our Form 10-K. This filing is available from the SEC or our website. All of our projections and other forward-looking statements represent our judgment as of today, and Cyclacel does not take any responsibility to update such information. With us today are Spiro Rombotis, President and Chief Executive Officer, Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, and Dr. Mark Kirschbaum, Senior Vice President and Chief Medical Officer. Spiro will begin with an overview of our business strategy and progress. Mark will provide details on Cyclacel's clinical programs, and Paul will provide financial highlights for the fourth quarter and full year of 2022, which will be followed by a Q&A session. At this time, I would like to turn the call over to Spiro. Thank you, Irina. Thank you everyone for joining us today for our quarterly business update. In 2022, we made excellent progress in our ongoing phase I/II clinical programs with oral fadraciclib, or fadra, and oral plogosertib, or plogo, in patients with solid tumors and lymphoma. Both programs are registration-directed and are well-positioned to deliver on key milestones during 2023. In the fadra study in patients with solid tumors and lymphoma, we have enrolled three patients at dose level 6A. Recent pharmacokinetic and pharmacodynamic data from this dose level suggest that we are achieving target engagement levels on continuous dosing, which are commensurate or better than those observed in dose level 5 patients. We will enroll three more patients at dose level 6A per protocol with the objective of determining the recommended phase II dose or RP2D. At our R&D day in October 2022, we reviewed clinical activity observed in the first five dose levels of the study. We were excited to see monotherapy partial responses or PRs after the first treatment cycle in lymphoma patients with both cutaneous T-cell lymphoma or CTCL and peripheral T-cell lymphoma or PTCL. This included a PR with a difficult-to-treat type of PTCL. In addition, 11 patients with various solid tumors achieved stable disease with target lesion reductions and a pancreatic patient maintained stable disease for five cycles of treatment. As we approach the completion of the phase II dose escalation stage of the fadra study, we look forward to starting the phase II proof of concept or PoC stage. This will consist of multiple cohorts defined by histology, which are designed to be recruited in parallel, thus avoiding the delays inherent in sequentially designed studies. We expect that cohorts may enroll at different rates. It is possible that the fastest ones will be those in which we have already seen anticancer activity during the dose escalation stage. Clinical data from this open label PoC stage will be reported as they become available. At the R&D day, we also reported exciting new findings from our plogo program, which focuses on PLK1 inhibition for the treatment of advanced solid tumors and lymphoma. Plogo has already shown early signals of anticancer activity at the first dose level in patients with non-small cell lung cancer and ovarian cancer. We also have evidence demonstrating plogo's differentiated biological profile. Dose escalation in the plogo study has advanced, and sites are currently submitting patients for dose level 4. Over the course of this year, we expect key data readouts from the phase I/II studies for fadra and plogo. We expect to report complete dose escalation data with fadra around the middle of the year. Initial data from the fadra phase II PoC stage are expected in the second half of 2023. Dose escalation in the plogo study continues, and we expect initial data in mid to late 2023. Before handing over to Mark, I would like to reiterate that the Cyclacel team is concentrating our efforts on bringing our two molecules to proof of concept stage in creating shareholder value. We are well on our way to achieving that with fadra, and we will soon be in a position to potentially do the same for plogo. We are fortunate to be working with world-class institutions across the globe who are participating in our studies. We believe that our medicines are differentiated from other molecules in their respective class with properties which may be best in class. I will now turn the call over to Dr. Mark Kirschbaum, our Chief Medical Officer, to provide details on recent clinical data. Mark? Thank you, Spiro. We are pleased with the single-agent activity and molecular profile of oral fadra and the encouraging progress of oral plogo in our phase I studies. Once the recommended phase II dose is determined in the ongoing 065-101 study with oral fadra, we will immediately move into phase II proof of concept stage, in which the primary objective is to assess activity and safety of the drug in relevant tumor types. At ENA 2022, in our R&D Day in October, we reported on the dose escalation part of the study. fadra was well-tolerated and escalated from dose levels 1- 5, which is 100 mg twice daily, Monday through Friday, for four weeks out of four. Dose level 5 is completed and can be considered safe. There have been no dose-limiting toxicities related to study drug. In dose levels up to 5, the only consistent side effect of the drug is nausea at manageable levels, typically grades 1 - 2. As per protocol, we escalated to dose level 6, which is 150 mg twice daily, Monday through Friday, for four weeks out of four. At that dose level, we observed two grade 3 dose-limiting toxicities at dose level 6, hyperglycemia in one patient and nausea in a second patient. Both were reversible after holding drug. In accordance with the protocol, we have enrolled three of a planned six patients at dose level 6 A, which is 125 mg twice daily, Monday through Friday, for four weeks out of four. At this stage of the study, we seek to optimize the dose and schedule and then commence the phase II stage. As reported, we have seen anticancer activity in the dose escalation up to level 5. Two out of three patients with T-cell lymphoma achieved PR, including a patient with a very aggressive angioimmunoblastic form of peripheral T-cell lymphoma. 11 of 15 patients with cervical, endometrial, liver, and ovarian cancers achieved stable disease with target lesion reductions as their best response. A pancreatic patient maintained stable disease for five cycles of treatment. These are promising responses for this earlier phase of clinical testing and may predict deeper responses in the phase II stage. With regard to our second oral fadra study, 065-102, in patients with acute myeloid leukemia and myelodysplastic syndromes, we are enrolling patients at dose level 5, which is 100 mg twice daily, Monday through Friday, for four weeks out of four. We look forward to providing an update on the 065-102 trial during the year. Let's now turn to our second program with plogosertib, our oral PLK1 inhibitor. We have reported initial encouraging results from 140-101, our phase I/II study of plogo in patients with advanced solid tumors and lymphoma. This study is currently enrolling at dose level 4, which is 15 mg once a day, Monday through Friday, for weeks one and three. This is a first-in-human study for oral plogo and, as is traditional, we have started at lower doses. We were therefore pleasantly surprised at this early stage of the study to observe stable disease at dose level 1 in 2 patients with non-small cell lung cancer for eight cycles and ovarian cancer for five cycles, respectively, and at dose level 2 in a patient with biliary tract cancer for three cycles. Published preclinical evidence suggests that low dose continuous administration may be an effective strategy for PLK1 inhibitors, as well as the more documented higher dose pulse type strategy. This is particularly true for plogo, given that it has a favorable PLK1 inhibitory profile and a shorter half-life, thus potentially minimizing toxicities. Our ongoing phase I/II trial of plogo is designed to target several important tumor types where the drug may show broad single-agent activity. This was observed across multiple pre-clinical models and in particular colon cancer, lymphoma, and small cell lung cancer. Our study efficiently evaluates both dose and schedule so as to optimize the recommended phase II dose for the proof of concept or cohort stage of the study. I will now turn the call over to Paul to review our fourth quarter and full year financial results. Thank you, Mark. As of December 31st, 2022, cash and cash equivalents totaled $18.3 million compared to $36.6 million as of December 31st, 2021. Net cash used in operating activities was $20.8 million for the 12 months ended December 31st, 2022, compared to $18.5 million for the same period of 2021. On a pro forma basis, cash and cash equivalents totaled $23 million, which includes $4.7 million of R&D tax credits receivable in the second quarter of 2023. The company estimates that its available cash will fund currently planned programs into the fourth quarter of 2023. Research and development, or R&D, expenses were $6.7 million for the three months ended December 31st, 2022, as compared to $4.6 million for the same period in 2021. R&D expenses related to fadra were $5.3 million for the three months ended December 31st, 2022, as compared to $3.4 million for the same period in 2021 due to the increase in clinical trial costs of $0.3 million associated with ongoing clinical trials evaluating fadra in the phase I/II study, an increase of $1.6 million in non-clinical expenditures. R&D expense related to plogo were $1.3 million for the three months ended December 31st, 2022, as compared to $1.1 million for the same period in 2021 due to clinical trial costs associated with the plogo phase I/II study. General and administrative expenses for the three months ended December 31st, 2022 were $2.1 million compared to $1.9 million for the same period of the previous year due to an increase in employment and professional costs. Total other expense net for the three months ended December 31st, 2022 was $0.2 million compared to an income of $43,000 for the same period of the previous year. The decrease of $0.2 million for the three months ended December 31st, 2022 is primarily related to foreign exchange adjustments. United Kingdom research and development tax credits were $ 1.6 million for the three months ended December 31st, 2022, compared to $ 1.2 million for the same period of the previous year and are directly correlated to qualifying research and development expenditure. Net loss for the three months ended December 31st, 2022 was $7.4 million compared to $5.3 million for the same period in 2021. Operator, we are now ready to take questions. At this time, if you would like to ask a question, please press star one on your telephone keypad. Again, to ask a question that is star one. To remove yourself from the queue that is star two. We'll take a question from Jonathan Aschoff of ROTH MKM. Your line is open. Thank you, guys. Hi. Just a brief first question. Is that R&D rate kind of a minimum new quarterly rate? You know, such that the 4Q that'll be at least a level in each of the 2023 quarters. Jonathan, thanks for the question. It will be for the first quarter, but in the United Kingdom they are changing the tax rate, so it will drop from $ 4.7 million probably down to about $ 2 million a quarter going forward. You're saying that R&D is only gonna be $2 million a quarter going forward? No, I thought you asked for the R&D tax credit. No, no, no. I'm, I'm asking for your GAAP reported R&D. The R&D will be consistent with the fourth quarter going forward into 2023. Yes. Okay. Thank you. The second question is, what can you say about the indications in which fadra and plogo are, you know, already looking the most effective? This is Spiro. Thank you, Jonathan. I think we can say that the lymphoma indication is the one that we feel the most encouraged, having seen early single-agent responses without toxicity in patients. Obviously, as we open the phase II, this indication maybe together with women's cancers like endometrial and ovarian, are the ones that will likely enroll the fastest. The reason of course is that physicians will find it easier to persuade patients to go on these protocols given the indication of previous activity. Going beyond that, we think that the other type of lymphoma B- cell is also a likely candidate. We know that other drugs in this space have reported recent in ASH activity in B- cell lymphoma, but they had enormous toxicities such as tumor lysis syndrome that has not been reported for fadraciclib in these studies. We expect some other women's cancers and possibly colorectal and liver cancer might be of interest given early indication of activity. Lymphoma and women's cancers are the ones that we feel most comfortable. For plogo, I think it's early days. We're also seeing prolonged stable disease in the very first dose level, which is almost at homeopathic levels in lung and also ovarian and biliary. We need to wait for one or two more dose levels before we can suggest that we are comfortable, let alone enthusiastic, for any specific indication at this point. Okay. Thank you. Are you contemplating any kind of combination therapy or just, you know, running for the single agent approval goal as fast as you can? That is certainly our primary objective in the event that we continue to see single agent activity. We all know, the combination strategy, although may producing substantial revenue opportunity, does take more time and more capital. The protocol as written for both fadra and plogo allows for combinations, and work is underway not only to prepare for that, but also to do preclinical work to assess combinability and safety of fadra, for example, with other agents that are suitable depending on the tumor type. It's fair to say, as you correctly pointed out, that our primary goal is to see if we can get a monotherapy indication developed up until PoC, and then approach regulators. Okay. Lastly, this is a quick one. What can you say about enrollment numbers, you know, between your last call and this call versus the second and third quarter call? I think this is a question for Mark. Yeah. Enrollment is going very quick on both studies. We pretty much fill all the slots the day we open. Yeah, we don't see any problem there. Yeah, I mean, it seems to actually be fairly quick, whereas a lot of companies I'm noticing... Yeah Kinda like they still have this COVID hangover or, something. We didn't have any of that. That's great. Thank you very much. Fortunately, we, yeah, I think partly because we're oral and because the drug is very well tolerated. You know, the investigators have been very eager to put patients on. Thank you very much. Thank you, Jonathan. Once again, to ask a question, that is star one on your telephone keypad. We'll move next to Ahu Demir of Ladenburg. Your line is open. Good afternoon. Thank you so much for taking my question. My first question is looking at the 065-101 and 065-102 studies of fadra, do you see similar safety profiles in the patients given the populations are very different? Thank you for your question, Ahu. This is a question for Mark. Yes. Yeah, we haven't seen extraordinary problems in the leukemia study. We actually have no SAEs reported there. In fadra, in the solid tumor trial, we've been clean on them all the way through to the current dose level. Yeah, I don't see any difference between the two. Thank you. My follow-up question is on the target engagement. Do you do any target engagement work, and are we going to see any data from those, both for fadra ciclib and plogo? We are certainly doing target engagement work. This is central to our understanding of both drugs. Obviously, fadra is more advanced, and I would like Mark to speak specifically on what type of studies we're doing to confirm exposure over threshold, which is critical for such agents, but also is important for us as we build confidence about enrolling a successful phase II. I think many companies rush into phase II without fully understanding pharmacodynamic exposure as well as effect on pharmacodynamic markers, and then try to sort of step back from phase II and see if they can correct the problem. Well, that becomes a quagmire. We are gonna be patient and develop the target engagement information as it comes from different dose levels and therefore pick the optimal dose in phase II. Mark, would you like to specifically discuss target engagement methodology? If you want to. Well, I'm not sure exactly what you mean, but target engagement was done from before the study started. We have an established set of values for which we know that CDK2 and CDK9 are inhibited by the drug, which has been our benchmark against which we've been looking at our, you know, current PKs and PDs as we're moving forward. As far as PDs go, I think what you, what we're trying to get at is that we're now, particularly in these dose levels that we're at now, we are certainly seeing the targets being hit that we anticipate. In other words, we believe that this drug is a MEK inhibitor and MCL-1 inhibitor, and we're seeing that activity in the PD samples that are drawn on the current patients that are involved. Is that the answer to the question? Yes, it is. My last question is for Paul. Paul, on the SG&A side, are we expecting a similar trend moving forward in the subsequent quarters? Ahu, yes, we are. It sort of sit around $2 million-$2.2 million on a quarterly basis. Thank you very much for taking my questions. Thank you, Ahu. Let me just add as a segue to Mark's comment that we're also seeing Cyclin E levels coming down, which is also an important target part of the CDK2 target profile of fadra. We're very pleased that we're seeing this level of confirmatory activity in patient samples. Thank you. Our next question is from Jeff Jones of Oppenheimer. Good afternoon, guys, thanks for taking the question. Two questions. What do you need to see in the six AR to have comfort to move ahead into the proof of concept cohorts? Over how many cycles do you need to see that? On the financial side, how much cash is needed to complete the three ongoing clinical studies? How much additional are you thinking you need to do the proof of concept study for fadra? Thank you. I think your first question, Jeff, is for Mark. Yes, please. Yeah, I can take that quickly. That's a happy question. I mean, the good news is that we already know from the PD that we have on the patients in that sample that we're hitting the targets that we wanna hit. That looks good. 6A looks good to us. What we have to do now is just confirm tolerability. We need to complete this first dose level, and that'll happen very soon. If that goes through, we'll go to six patients and call it an acceptable dose. That's coming up soon. Let me turn it back to Spiro for the other questions. It's actually Paul's question. Yeah. Let me, yeah, let me take that question. Thank you very much. As we've mentioned, we have cash that runs through to the end of this year, Q4 2023. The way that we have budgeted that is to clearly run our phase II up into the phase II for fadra, the oral fadra in the solid tumors and lymphoma. As once we get through RP2D, start the phase II, we're budgeted to get into PoC, and we believe with our milestones that we'll be able to report out of that PoC in this current year within the current cash envelope. The other two studies we're currently assuming we will get to dose escalation again within 2023. Thank you. Once again, that is star one to ask a question. We'll move next to Kemp Dolliver of Brookline Capital Markets. Your line is open. Hi, this is Kemp Dolliver. Quickly on the timing of readouts and the cadence, what's your sense as to how they will play out during the year? Hello, Kemp. Thanks for your question. We think that obviously declaration of RP2D for fadra, the 065-101 study in solid tumors and lymphoma, is probably the most important milestone for the first half of the year. The company plans to make an announcement once we reach that critical milestone. As you already are aware, the protocol is seamless. It moves straight into phase II. We expect the next batch of milestones for that study will come from initial cohorts that will roll fastest. We mentioned in a previous question that we think that's likely to be lymphoma and women's cancers. Since it's a futility study, it's based on X responses over Y enrollees in that cohort, we expect to report that fairly early as other cohorts may take longer to enroll. When it comes to the leukemia study, I think that one is picked up enrollment pace. We're able to also get FDA agreements to jump a dose level or two based on safety in the solid tumor study. That's as Paul just mentioned, we'll probably get to the through the dose escalation stage to the proximity of RP2D. There may be some crosstalk between the leukemia study and the solid tumor study. That often happens. Of course, we always be looking to finish the plogosertib phase I dose escalation component and hopefully get as close to RP2D as we can with important qualification. In that program, low dose may be sufficient to achieve target engagement and PD levels. That remains to be determined, of course, but that is a potential readout as well within 2023. That's very helpful. Thank you. You know, how are you thinking about the prioritization, depending on, a gain, you know, we're in an environment where the incremental dollars have been harder to get. And you may get all the capital you need, quickly or it may be a challenge. Is it fair to assume that fadra going into phase II, if you had to focus on one priority initially, that's where you would direct the capital? Yes. Well, we live obviously in risk mitigation across all programs. You are correct. In that situation you just portrayed, fadra, the 065-101 study in solid tumors and lymphoma is a number one priority. We intend to report early readouts from that study this year, as we think this is critical to strategic parties that are approaching the company to discuss interest in this program. There are two reasons for that in my opinion. One is that this has been a field of great interest to pharma for many years. As many of the audience know, there have been a large number of programs in the next generation CDK family. Fadra is one of the leading, if not the leading program in this area. It has obviously been on the radar of many companies. The second reason is the scarcity value of this drug. I think that as we learn from ASH and earlier on other conferences of 2022, fadra is so far the only drug in the next generation CDK family to have single agent activity and a good tolerability profile. Especially if we think about the unmet medical need in lymphomas, in particular T-cell lymphoma and endometrial, ovarian, and other women's cancers. I think it's clear to see why for us this remains by far the biggest value driver for the company in the year going forward. Very helpful. Thank you. Thank you, Kemp. It does appear that we have no further questions at this time. I have to return the call to our host for any concluding remarks. Thank you, operator. Our thanks to all of you for joining Cyclacel's fourth quarter and full year earnings call. The key takeaway from today's call is that as momentum builds with our two clinical programs, their potential of becoming important anticancer therapeutics in solid tumors and lymphoma is becoming apparent in both medical and industry circles. As a reminder, our key milestones for 2023 are report final data from dose escalation stage and recommended phase II dose determination from the 065-101 study of oral fadraciclib in patients with advanced solid tumors and lymphoma. First patient dose with oral fadra in phase II proof of concept stage of 065-101 study in patients with advanced solid tumors and lymphoma. Report interim phase I data from 140-101 study of oral plogosertib in patients with advanced solid tumors and lymphoma. Report interim data from initial cohorts in phase II proof of concept study of 065-101 with oral fadraciclib in patients with advanced solid tumors and lymphoma. Report interim data from dose escalation stage of 065-102 study with oral fadraciclib in patients with advanced leukemias. Report final data from dose escalation stage of 140-101 study with oral plogosertib in advanced solid tumors and lymphoma. We look forward to providing you with further updates and hope to meet some of you at upcoming conferences. Operator, at this time, you may end the call. This does conclude today's conference. You may now disconnect your lines, and everyone, have a great day.